ELDN
Eledon Pharmaceuticals, Inc.
Next earnings Aug 12, 2026 · consensus $-0.18 EPS
Last earnings -0.5% on 2026-05-13
$3.78
▲ +3.56%$3.78▲ +45.38%
over 1Y
L $1.39EODHDH $4.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.6%
1W-0.8%
1M-3.1%
3M+33.6%
YTD+133.3%
1Y+45.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Conservative balance sheet (liabilities/equity 0.40x).
Revenue (FY2016) $0.00 · FY2016
Eledon Pharmaceuticals, Inc. shows $0.00 in FY2016 revenue, and -56.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$36.9M | -$88.4M | -$43.0M | — | — |
| Net income | -$34.5M | -$88.0M | -$117M | -$36.2M | -$45.6M |
| Diluted EPS | -$2.33 | -$6.16 | -$4.73 | -$0.66 | -$0.52 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$264M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-15.9%
FCF yield-21.7%
Quality & risk
ROIC (est.)-41.9%
Free cash flow-$62.4M
Total debt—
Net cash$22.8M
Altman Z-Score2.01 grey
Piotroski F-Score0/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+26.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Charter / bylaws change2026-06-22
- 8-K Earnings results2026-05-13
- 10-Q Quarterly report2026-05-13
- S-3 Shelf registration (potential raise)2026-05-01
- DEF 14A Proxy statement2026-04-30
- 8-K Earnings results2026-03-19
- 10-K Annual report2026-03-19
- 8-K Unregistered share sales2026-01-02
- 8-K Earnings results2025-11-14
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-182026-06-22open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗EFFECTFiling2026-05-11open ↗CORRESPFiling2026-05-07open ↗UPLOADFiling2026-05-07open ↗S-3Filing2026-05-01open ↗DEFA14AFiling2026-04-30open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEF 14APeriod ending 2026-06-182026-04-30open ↗SCHEDULE 13GFiling2026-04-27open ↗
Frequently asked
- Is Eledon Pharmaceuticals, Inc. (ELDN) a buy?
- ELDN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.40x).
- What is Eledon Pharmaceuticals, Inc.'s quality score?
- ELDN scores 35.46153846153846/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001404281, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 6:12:30 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.